Biotech entity
pharma is the sole category represented across all 1 tracked stories. Mineralys Therapeutics is most often covered alongside AstraZeneca, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 3.6 for the broader beat in this window.
Last mentioned: Mar 13, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Mineralys Therapeutics is most often covered alongside AstraZeneca, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 3.6 for the broader beat in this window. Their average consequence score of 5 runs below the beat's 6 for that window. We currently track 1 Biotech story that mention Mineralys Therapeutics, all published on March 12, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 22 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Mineralys Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Mineralys Therapeutics (MLYS) reported a narrower-than-expected Q4 2025 loss and confirmed the FDA's acceptance of its New Drug Application for lorundrostat. The company is now pivoting toward commercial readiness for its lead hypertension candidate while maintaining a robust clinical pipeline in chronic kidney disease.
Mineralys Therapeutics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
